Ten years ago, I joined
@PalantirTech because the problems felt impossible to ignore. Deploying software for mission-critical systems in life sciences and aerospace where failure wasn’t abstract. That weight shaped how I think about work.
I’m bringing that same weight to something new.
Today, we’re announcing
@MendraInc with $82 million to acquire, develop, and commercialize therapies for rare diseases. These conditions affect millions of people, yet most still have no approved treatment and are often undiagnosed or misdiagnosed. Many of these conditions present in childhood.
Becoming a parent made this personal. It sharpened the stakes. Rare disease development and commercialization is a systems problem. Advances in data orchestration and AI now make it possible to identify patients and accelerate delivery of therapeutics in ways that simply weren’t feasible years ago.
Immensely grateful to my Palantir family for the last decade, and to the team I’m building with at
@MendraInc. Let’s go!